검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 3개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Brentuximab Vedotin | Polatuzumab Vedotin | Acalabrutinib |
Overview Company | Seagen / Takeda | Roche / Genentech | Epizyme, Inc. |
Overview Modality | ADC | ADC | ADC |
Overview Target | Hodgkin Disease | FRα | Diffuse Large B-Cell Lymphoma |
Overview Indication | Hodgkin Lymphoma | Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy |
Overview Phase | APPROVED | PHASE_3 | PHASE_2 |
Overview Status | ACTIVE | RECRUITING | RECRUITING |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | inhibits B-cell receptor signaling |
MoA Biomarker | biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic | CD20 expression | biomarkers and inhibited the B-cell receptor pathway signaling in longitudinal samples from patients with rel |
PK/PD Half-life | — | 12.2 h | — |
PK/PD Species | Mouse | Rat, 048) | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro | Rat | Mouse, In vitro |
PK/PD Experiment | PD | pharmacokinetic | Pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, Mouse, Rat, 048) | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, NHP | Mouse, Rat, NHP | Rat |
Toxicology Major finding | Hepatotoxicity : Monitor liver enzymes and bilirubin ( 5 | Hepatotoxicity: Monitor liver enzymes and bilirubin | Hepatotoxicity, Including Drug Induced Liver Injury: Monitor hepatic function throughout tr |
Clinical Primary efficacy | ORR 86% | ORR 95% | ORR 82.4% |
Clinical ORR | 86% | 95.0% | 82.4% |
Clinical PFS | — | — | NA |
Clinical OS | — | — | NA |
Clinical Result source | ClinicalTrials.gov NCT01712490 | ClinicalTrials.gov NCT03677141 | ClinicalTrials.gov NCT03932331 |
Clinical Data Tier / Score | B · 89 | S · 92 | C · 71 |
Clinical Program phase | APPROVED | PHASE_3 | PHASE_2 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 3개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Brentuximab Vedotin | Polatuzumab Vedotin | Acalabrutinib |
Overview Company | Seagen / Takeda | Roche / Genentech | Epizyme, Inc. |
Overview Modality | ADC | ADC | ADC |
Overview Target | Hodgkin Disease | FRα | Diffuse Large B-Cell Lymphoma |
Overview Indication | Hodgkin Lymphoma | Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy |
Overview Phase | APPROVED | PHASE_3 | PHASE_2 |
Overview Status | ACTIVE | RECRUITING | RECRUITING |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | inhibits B-cell receptor signaling |
MoA Biomarker | biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic | CD20 expression | biomarkers and inhibited the B-cell receptor pathway signaling in longitudinal samples from patients with rel |
PK/PD Half-life | — | 12.2 h | — |
PK/PD Species | Mouse | Rat, 048) | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro | Rat | Mouse, In vitro |
PK/PD Experiment | PD | pharmacokinetic | Pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, Mouse, Rat, 048) | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, NHP | Mouse, Rat, NHP | Rat |
Toxicology Major finding | Hepatotoxicity : Monitor liver enzymes and bilirubin ( 5 | Hepatotoxicity: Monitor liver enzymes and bilirubin | Hepatotoxicity, Including Drug Induced Liver Injury: Monitor hepatic function throughout tr |
Clinical Primary efficacy | ORR 86% | ORR 95% | ORR 82.4% |
Clinical ORR | 86% | 95.0% | 82.4% |
Clinical PFS | — | — | NA |
Clinical OS | — | — | NA |
Clinical Result source | ClinicalTrials.gov NCT01712490 | ClinicalTrials.gov NCT03677141 | ClinicalTrials.gov NCT03932331 |
Clinical Data Tier / Score | B · 89 | S · 92 | C · 71 |
Clinical Program phase | APPROVED | PHASE_3 | PHASE_2 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교